Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description in

Entry into a Material Definitive Agreement. On August 13, 2026, OPKO Health, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the initial Note Purchase Agreement dated July 17, 2024 (the “Original Agreement”; and as amended by the Amendment, the “Amended Agreement”) with certain purchasers party thereto from time to time, its wholly-owned subsidiaries OPKO Biologics Ltd. (“OBL”) and EirGen Pharma Limited (“EirGen”) as guarantors (OBL and EirGen collectively, the “Guarantors…

Results of Operations and Financial Condition. On July 27, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended June 30, 2026. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended June 30, 2026, as well as provide financial guidance. A copy of the press release…

Results of Operations and Financial Condition. On April 28, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2026. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2026, as well as provide financial guidance. A copy of the press releas…

Director — Subbarao V. Uppaluri, Ph.D.: Dr. Subbarao V. Uppaluri was appointed as a new director to fill the vacancy left by Dr. Richard Krasno's passing.

Results of Operations and Financial Condition. On February 26, 2026, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter and year ended December 31, 2025. The press release also contains information on how to access the conference call the Company is hosting to discuss its financial and operating results for the fourth quarter and year ended December 31, 2025, as well as provide business updates and financial guidance. A copy…

Results of Operations and Financial Condition. On October 29, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended September 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the third quarter ended September 30, 2025, as well as provide financial guidance. A copy of the pr…

Results of Operations and Financial Condition. On July 31, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended June 30, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended June 30, 2025, as well as provide financial guidance. A copy of the press release…

The filing details compensation arrangements, including stock options and bonuses for executive officers.

Results of Operations and Financial Condition. On April 30, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2025. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2025, as well as provide financial guidance. A copy of the press releas…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Steven D. Rubin Date: April 1, 2025 Name: Steven D. Rubin Title: Executive Vice President-Administration

Entry into a Material Definitive Agreement. As previously reported, on March 27, 2025, OPKO Health, Inc., a Delaware corporation (the “ Company ”), entered into exchange agreements (the “ Exchange Agreements ” and each an “ Exchange Agreement ”) with certain institutional holders (the “ Noteholders ”) of the Company’s outstanding 3.75% Convertible Senior Notes due 2029 (the “ Notes ”), pursuant to which the Noteholders agreed to exchange $152,471,000 aggregate principal amount of Notes for an…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPKO Health, Inc. By: /s/ Steven D. Rubin Date: March 28, 2025 Name: Steven D. Rubin Title: Executive Vice President-Administration

Entry into a Material Definitive Agreement. On March 27, 2025, OPKO Health, Inc., a Delaware corporation (the “ Company ”), entered into exchange agreements (the “ Exchange Agreements ” and each an “ Exchange Agreement ”) with certain institutional holders (the “ Noteholders ”) of the Company’s outstanding 3.75% Convertible Senior Notes due 2029 (the “ Notes ”), pursuant to which the Noteholders have agreed to exchange (the “ Exchange ”) $152,471,000 aggregate principal amount of Notes (the “…

Entry into a Material Definitive Agreement. On March 10, 2025, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”). Pursuant to the Purchase Agreement, Seller has agreed to sell and assign to Buyer, and Buyer has agreed to purchase…

Results of Operations and Financial Condition. On February 27, 2025, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended December 31, 2024. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the fourth quarter ended December 31, 2024, as well as provide financial guidance. A copy of the pr…

Results of Operations and Financial Condition. On November 7, 2024, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended September 30, 2024. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended September 30, 2024, as well as provide financial guidance. A copy of the p…

Termination of a Material Definitive Agreement. Effective September 16, 2024, BioReference Health, LLC, a Delaware limited liability company (“ BioReference ”), a subsidiary of OPKO Health, Inc. (“ OPKO ” or the “ Company ”), repaid in full all of its obligations under and terminated that certain Amended and Restated Credit Agreement, dated as of August 30, 2021, by and among BioReference, certain of its subsidiaries, as borrowers or guarantors, the lenders party thereto, and JP Morgan Chase…

Completion of Acquisition or Disposition of Assets. As previously reported, on March 27, 2024, the Company, BioReference and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”), pursuant to which BioReference and the Company agreed to sell and assign to Buyer, and Buyer agreed to purchase and assume from BioReference and the Company, certain assets and liabilities of BioReference’s laboratory tes…

Results of Operations and Financial Condition. On August 7, 2024, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended June 30, 2024. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the second quarter ended June 30, 2024, as well as provide financial guidance. A copy of the press release…

The filing details compensation arrangements and grants for executive officers, not a management change.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description in

Entry into a Material Definitive Agreement. On July 17, 2024, OPKO Health, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Agreement”) with certain purchasers party thereto from time to time, its wholly-owned subsidiaries OPKO Biologics Limited (“OBL”) and EirGen Pharma Ltd. (“EirGen”) as guarantors (OBL and EirGen collectively, the “Guarantors”), and HCR Injection SPV, LLC as agent (“Agent”), pursuant to which the Company issued senior secured notes (“Notes”) in aggregate i…

Results of Operations and Financial Condition. On May 7, 2024, OPKO Health, Inc. (the “Company”) issued a press release announcing operating and financial highlights for the quarter ended March 31, 2024. The press release also contains information on how to access the conference call the Company is hosting to provide a business update and discuss its financial and operating results for the first quarter ended March 31, 2024, as well as provide financial guidance. A copy of the press release i…

Entry into a Material Definitive Agreement. On March 27, 2024, OPKO Health, Inc., a Delaware corporation (“ OPKO ”), its wholly owned subsidiary, BioReference Health, LLC (“ BioReference ” and together with OPKO, “ Seller ”), and Laboratory Corporation of America Holdings, a Delaware corporation (“ Buyer ”), entered into an Asset Purchase Agreement (the “ Purchase Agreement ”). Pursuant to the Purchase Agreement, Seller has agreed to sell and assign to Buyer, and Buyer has agreed to purchase…